Effect of altering endogenous gonadotrophin concentrations on the kinetics of testicular germ cell turnover in the bonnet monkey (Macaca radiata)

The role of FSH and diurnal testosterone rhythms in specific germ cell transformations during spermatogenesis were investigated using DNA flow cytometry and morphometry of the seminiferous epithelium of the adult male bonnet monkey (Macaca radiata), the endogenous hormone levels of which were altered by two different protocols. (1) Active immunization of five monkeys for 290 days using ovine FSH adsorbed on Alhydrogel resulted in the neutralization of endogenous FSH, leaving the LH and diurnal testosterone rhythms normal. (2) Desensitization of the pituitary gonadotrophs of ten monkeys by chronically infusing gonadotrophin-releasing hormone analogue, buserelin (50 micrograms/day release rate), via an Alzet pump implant (s.c.) led to a 60-80% reduction in LH and FSH as well as total abolition of testosterone rhythms. The basal testosterone level (3.3 +/- 2.0 micrograms/l), however, was maintained in this group by way of an s.c. testosterone silicone elastomer implant. Both of the treatments caused significant (P < 0.01) nearly identical reduction in testicular biopsy scores, mitotic indices and daily sperm production rates compared with respective controls. The germ cell DNA flow cytometric profiles of the two treatment groups, however, were fundamentally different from each other. The pituitary-desensitized group exhibited a significant (P < 0.001) increase in 2C (spermatogonial) and decrease in 1C (round spermatid) populations while S-phase (preleptotene spermatocytes) and 4C (primary spermatocytes) populations were normal, indicating an arrest in meiosis caused presumably by the lack of increment in nocturnal serum testosterone. In contrast, in the FSH-immunized group, at day 80 when the FSH deprivation was total, the primary block appeared to be at the conversion of spermatogonia (2C) to cells in S-phase and primary spermatocytes (4C reduced by > 90%). In addition, at this time, although the round spermatid (1C) population was reduced by 65% (P < 0.01) the elongate spermatid (HC) population showed an increase of 52% (P < 0.05). This, taken together with the fact that sperm output in the ejaculate is reduced by 80%, suggests a blockade in spermiogenesis and spermiation. Administration of booster injections of oFSH at time-points at which the antibody titre was markedly low (at days 84 and 180) resulted in a transient resurgence in spermatogenesis (at day 180 and 228), and this again was blocked by day 290 when the FSH antibody titre increased.

The efficacy of a single chain recombinant equine luteinizing hormone (reLH) in mares: Induction of ovulation, hormone profiles, and inter-ovulatory intervals

The objectives of this study were to determine the efficacy of recombinant equine luteinizing hormone (reLH) in shortening the time to ovulation in cycling mares and to determine the effects of treatment on endogenous hormones and inter-ovulatory intervals. In study 1, mares of light horse breeds (3-20 years) were treated with either a vehicle, various doses of reLH, or human chorionic gonadotropin (hCG). Cycling mares were examined by palpation and ultrasound per rectum daily or every 12 h from the time of treatment to ovulation. In studies 2 and 3, jugular blood samples were collected daily or every 12 h from the time of treatment to ovulation for analysis of LH, follicle stimulating hormone (FSH), estradiol-17 beta (E-2), and progesterone (P-4) by radioimmunoassays (RIA). Increasing doses of reLH (0.3, 0.6, 0.75, and 0.9 mg) showed increasing effectiveness at inducing ovulation within 48 h of treatment. Treatments with the 0.75 and 0.9 mg doses of reLH resulted in 90% and 80% ovulation rates, which were similar to hCG treatment (85.7%). Except for the early rise in LH after treatment with 0.5, 0.65, and 1.0 mg of reLH, hormone profiles appeared to be similar between control and treated cycles. Inter-ovulatory intervals were similar between control and treatment cycles. In conclusion, reLH is a reliable and effective ovulatory agent that does not significantly alter endogenous hormone profiles or affect inter-ovulatory intervals.(c) 2007 Elsevier B.V. All rights reserved.

Alteration of Hormone Levels in Transgenic Tobacco Plants Overexpressing the Rice Homeobox Gene OSH1

The rice (Oryza sativa L.) homeobox gene OSH1 causes morphological alterations when ectopically expressed in transgenic rice, Arabidopsis thaliana, and tobacco (Nicotiana tabacum L.) and is therefore believed to function as a morphological regulator gene. To determine the relationship between OSH1 expression and morphological alterations, we analyzed the changes in hormone levels in transgenic tobacco plants exhibiting abnormal morphology. Levels of the plant hormones indole-3-acetic acid, abscisic acid, gibberellin (GA), and cytokinin (zeatin and trans-zeatin [Z]) were measured in leaves of OSH1-transformed and wild-type tobacco. Altered plant morphology was found to correlate with changes in hormone levels. The more severe the alteration in phenotype of transgenic tobacco, the greater were the changes in endogenous hormone levels. Overall, GA1 and GA4 levels decreased and abscisic acid levels increased compared with wild-type plants. Moreover, in the transformants, Z (active form of cytokinin) levels were higher and the ratio of Z to Z riboside (inactive form) also increased. When GA3 was supplied to the shoot apex of transformants, internode extension was restored and normal leaf morphology was also partially restored. However, such GA3-treated plants still exhibited some morphological abnormalities compared with wild-type plants. Based on these data, we propose the hypothesis that OSH1 affects plant hormone metabolism either directly or indirectly and thereby causes changes in plant development.

牡丹花芽分化类型与促成连续二次开花

牡丹（Paeonia suffruticosa Andr.），芍药科芍药属植物，是我国的传统名花，因花朵硕大、花色丰富、花型齐全而显雍容华贵、富丽端庄，“惟有牡丹真国色，花开时节动京城”，深受人民的喜爱。人们在欣赏牡丹的过程中，一方面为其艳丽多姿而赞叹，同时又为其自然花期较短且集中而遗憾，“弄花一年，看花十日”，因此，如何通过栽培等技术措施使牡丹连续开花，一直是牡丹研究者探索的重要课题。近年，在对牡丹栽培的系统研究中，发现不同牡丹品种的花芽分化类型（数量、梯度）直接影响其开花数量和开花次数。为了有效地利用不同类型的牡丹，选育出更多的丰花、同株可连续开花的品种，服务于牡丹的产业化生产，本试验对4个牡丹品种群的135个品种进行了同枝条芽数的统计分析及花芽分化梯度的划分，阐明了花芽分化类型与促成连续二次开花的关系。初步测定了具有促成连续二次开花习性的牡丹品种‘High Noon’不同芽位腋芽内源激素的含量，揭示了牡丹同株连续二次开花过程中不同芽位腋芽内源激素的生理变化规律，为解决牡丹同株花期短、不能同株连续开花的难题奠定了理论基础。本研究主要结果如下： 1、牡丹花芽分化类型与自然开花的关系 通过对135个牡丹品种花芽分化数量和梯度类型的调查，将同枝条的芽数聚类为少（3-4）、中等（5-7）、多（8-10）三类;将花芽分化梯度划分为小、中、大三种类型。芽数类型和花芽分化梯度类型均与品种群有一定的关系。中原品种群中90%的品种属于芽数少的类型，47%的品种属于分化梯度大的类型;日本品种群中73%的品种属于芽数中等的类型，52%的品种属于分化梯度中的类型;法国品种群和美国品种群品种调查数量较少，但大多数品种属于芽数中等的类型，分别占80%和44%，分化梯度小的品种分别占调查总数的40%和67%。绝大部分品种的腋花芽因在枝条上着生的位置不同而有明显的异质性，上部芽顶端优势强，萌动率和开花率均高，芽数多的品种中、下部芽在春天自然开花季节常处于休眠状态。 2、牡丹花芽分化类型与促成连续二次开花的关系 花芽分化数量的多少与梯度的大小直接影响着开花次数。花芽分化数量少、梯度大的品种不建议直接用于同株促成连续二次开花栽培;花芽分化数量中等或多、梯度小的品种可以实现同株促成连续二次开花，10个试验牡丹品种中的中原牡丹品种‘如花似玉（Ru Hua Si Yu）’和美国牡丹品种‘High Noon’具有同株连续二次开花能力，且二次开花率达75%以上，两次开花品质均优良。 3、‘High Noon’不同芽位腋芽内源激素与促成连续开花的关系 通过测定美国牡丹品种‘High Noon’同枝条不同芽位腋芽萌动前期、后期内源激素含量，结果表明：萌动后期不同芽位腋芽的GA3、IAA、ZRs含量增加，尤其1位芽、2位芽含量增加显著;萌动后期ABA含量则随着芽位自上而下增加显著，可能是导致下部芽继续保持休眠状态的主要原因;萌动后期下部芽的ABA/ZRs配比增幅较高，说明ABA/ZRs配比与芽的生长与休眠关系密切。

濒危植物大花黄牡丹种子休眠与萌发特性研究

本文以中国极危种大花黄牡丹种子为研究材料，对其种子生物学、休眠与萌发特性进行研究，采用变温层积和激素处理解除种子休眠，并通过生物抑制物测试、胚培养、激素含量动态变化的测定，研究种子休眠的原因，从根本上解决了大花黄牡丹迁地保护过程中种子繁殖的技术难题，并初步探讨了大花黄牡丹致濒因素与种子休眠及萌发特性的关系，结果表明： 1.大花黄牡丹种子饱实度高，活力强，种皮较坚硬，但不存在吸水障碍，干燥条件下易因失水而丧失活力。迁地保护冷室中盆播18个月方可出苗，出苗率约4%;变温层积实验表明该种具有典型的下胚轴休眠和上胚轴生长抑制。 2.胚组织培养表明：带胚乳和种皮的胚不能萌发，剥除种皮和胚乳后，胚根可萌发，胚芽不生长，GA3处理上胚轴可促进生长，说明种皮和胚乳是导致大花黄牡丹种子下胚轴休眠的关键因素，而上胚轴生长抑制与胚本身关系更密切。 3.抑制物质提取实验表明：大花黄牡丹种子胚乳、种皮、胚等各部位的浸提液均存在抑制小白菜种子萌发的物质，且抑制作用依次增强，说明胚乳和胚是其下胚轴休眠的主要原因。经过暖层积（15 ℃/90 d）种子（未解除上胚轴生长抑制）的胚根、子叶、胚轴浸提液对小白菜和已解除休眠的大花黄牡丹种子的萌发均有不同程度的抑制作用，并依次减弱，说明种胚本身的抑制物质是导致生理休眠的主要原因。 4.变温层积处理和外源激素实验表明：新鲜种子采收后15 ℃暖层积3个月生根率可达85%，下胚轴休眠解除对温度要求严格，高于或低于15 ℃及变温条件均不利于下胚轴萌发;暖层积90d、根长大于6 cm种子再经过60～80 d/ 5 ℃冷层积，即可有效解除大花黄牡丹种子上胚轴的生长抑制，出芽率达80%，最终出苗率68%。不同浓度GA3及不同处理时间促进上胚轴伸长实验结果显示，GA3　400 mg/L浸种根长大于1.5 cm的种子2 h，出芽率可达100%，可以完全解除上胚轴的生长抑制作用。 5.休眠萌发过程中种子各部位内源激素含量动态变化分析结果说明，初始状态脱落酸含量高是导致大花黄牡丹种子下胚轴休眠、上胚轴生长抑制的主要原因之一，且上胚轴抑制与子叶、下胚轴和根的脱落酸含量密切相关;同时认为种子各部位初始生长素含量水平低是导致其休眠的另一个主要原因;变温层积过程中胚各部位脱落酸含量的急剧下降和生长素的迅速升高是解除休眠的关键;同时发现赤霉素在解除休眠和促进萌发过程中起着重要的促进作用，外源GA3能够有效地打破上胚轴的深度休眠。玉米素核苷在休眠与萌发进程中变化趋势与生长素和赤霉素相似，说明其对种子胚根和上胚轴的萌发和生长具有一定的促进作用。

土壤干旱胁迫下沙棘休眠、萌芽期内源激素变化及外源GA_3的调节

研究了２年生中国沙棘（Ｈｉｐｐｏｐｈａｅ ｒｈａｍｎｏｉｄｓ）在土壤干旱胁迫下苗木含水量、内源激素水平与萌芽率关系以及萌芽关键期喷施外源ＧＡ３的作用。结果表明：土壤干旱胁迫使冬季休眠与春季萌芽期苗木含水量、内源ＧＡ１／３降低，内源ＡＢＡ明显提高，ＧＡ１／３ＡＢＡ下降，达到萌动所需的调控阈值的时间延迟，重度干旱下苗木萌芽延迟约２５ｄ，且萌芽后的枝生长十分缓慢；中度干旱下苗木萌芽延迟１０ｄ，萌芽后生长亦有所抑制。喷施８０ｍｇ／Ｌ外源ＧＡ３溶液可有效提高重度干旱下苗木内源ＧＡ１／３，降低ＡＢＡ含量，使ＧＡ１／３／ＡＢＡ提高，促进苗木提早萌芽及萌芽后生长；在适宜水分及中度干旱下，沙棘苗木外施ＧＡ３对萌芽及其生长作用不明显。

干旱对沙棘休眠、萌芽期内源激素及萌芽特性的影响

以 2a生中国沙棘为试验材料 ,研究了土壤干旱胁迫下沙棘苗木水分生理状况 ,内源GA1 3 及ABA水平与萌芽率的关系 ,结果表明 :土壤干旱胁迫导致苗体含水量、水势、自由水含量下降 ,显著提高冬季休眠与春季萌动期的内源ABA水平而降低内源GA1 3 含量 ,GA1 3 ABA降低 ,较晚达到萌动所需的调控阈值 ,萌芽延迟。重度胁迫下苗木延迟达 2 5d且萌芽后生长缓慢。长期土壤中度干旱条件下沙棘苗萌芽期亦略有延迟 ,萌芽后生长略有抑制

Lack of effects of isoflavones on the lipid profile of Brazilian postmenopausal women

Objective: To evaluate the effects of soy isoflavone supplementation on profile lipid and endogenous hormone levels. Methods: In this double-blind, placebo-controlled Study, 47 post menopausal women 47-66 v of age received 40 mg of isoflavone (n = 25) or 40 mg of casein placebo (11 = 22). Cardiovascular risk factors were assessed by evaluating lipid profile at baseline and after 6 mo of treatment. To examine the effects of this regime on endogenous hormone levels, follicle-stimulating hormone and beta-estradiol were measured. Urinary isoflavone concentrations (genistein and daidzein) were measured as markers of both compliance and absorption using high performance liquid chromatography. Baseline characteristics were compared by the unpaired Student`s t-test. Within-group changes were determined by paired Student`s t-test and comparison between the isoflavone and casein placebo groups were determined by analysis of variance. Results: Lipid levels (low-density lipoprotein and total cholesterol) similarly decreased in both,groups. High-density lipoprotein increased significantly in both groups and cannot thus be attributable to treatment: the reason for Such variation is unknown and can be attributed to chance or to bias (even that of a real placebo effect in both groups or perhaps in spontaneous changes in exercise and dietary habits of patients after their inclusion). Furthermore, in both groups very low-density lipoprotein and triacylglycerol levels increased in a non-significant manner. Conclusion: The results of the present Study do not support any biologically significant estrogenic effects of isoflavone on the parameters assessed. Further research will he necessary to definitively assess the safety and efficacy of isoflavone. (C) 2008 Elsevier Inc. All rights reserved.

Caracterização térmica (TG/DTG, DTA, DSC, DSC-fotovisual) de Hormônios bioidênticos (estriol estradiol)

Bioidentical hormones are defined as compounds that have exactly the same chemical and molecular structure as hormones that are produced in the human body. It is believed that the use of hormones may be safer and more effective than the non-bioidentical hormones, because binding to receptors in the organism would be similar to the endogenous hormone. Bioidentical estrogens have been used in menopausal women, as an alternative to traditional hormone replacement therapy. Thermal data of these hormones are scarce in literature. Thermal analysis comprises a group of techniques that allows evaluating the physical-chemistry properties of a drug, while the drug is subjected to a controlled temperature programming. The thermal techniques are used in pharmaceutical studies for characterization of drugs, purity determination, polymorphism identification, compatibility and evaluation of stability. This study aims to characterize the bioidentical hormones estradiol and estriol through thermal techniques TG/DTG, DTA, DSC, DSC-photovisual. By the TG curves analysis was possible to calculated kinetic parameters for the samples. The kinetic data showed that there is good correlation in the different models used. For both estradiol and estriol, was found zero order reaction, which enabled the construction of the vapor pressure curves. Data from DTA and DSC curves of melting point and purity are the same of literature, showed relation with DSC-photovisual results. The analysis DTA curves showed the fusion event had the best linearity for both hormones. In the evaluation of possible degradation products, the analysis of the infrared shows no degradation products in the solid state

Critical determinants of estrogen receptor -mediated agonist activity

Exogenous ligands that bind to the estrogen receptor (ER) exhibit unique pharmacologies distinct from that observed with the endogenous hormone, 17β-estradiol (ED. Differential activity among ER ligands has been observed at the level of receptor binding, promoter interaction and transcriptional activation. Furthermore, xenoestrogens can display tissue-specific agonist activity on the cellular level, functioning as an agonist in one tissue and as an antagonist in another. That the same ligand, functioning through the same receptor, can produce differing agonist responses on the cellular level indicates that there are tissue-specific determinants of agonist activity. In these studies critical molecular determinants of agonist activity were characterized for several cell types. In the normal and neoplastic myometrium a proliferative response was dependent upon activation of AF2 of the ER, functioning as a determinant of agonism in this cell type. Progesterone receptor (PR) ligands transdominantly suppressed ER-mediated transcription and proliferation in uterine leiomyoma cells, indicating that ER/PR cross-talk can modulate agonist activity in a myometrial cell background. In the breast, the agonist response to ER ligands was investigated by employing a functional genomics approach to generate gene expression profiles. Treatment of breast cancer cells with the selective estrogen receptor modulator tamoxifen largely recapitulated the expression profile induced by treatment with the agonist E2, despite the well-characterized antiproliferative effects produced by tamoxifen in this cell type. While the expression of many genes involved in regulating cell cycle progression, including fos, myc, cdc25a, stk15 and cyclin A, were induced by both E2 and tamoxifen in breast cells, treatment with the agonist E2 specifically induced the expression of cyclin D1, fra-1 , and uracil DNA glycosylase. These results suggest that the inability of tamoxifen to transactivate expression of only a few key genes, functioning as cellular gatekeepers, prevent tamoxifen-treated breast cells from entering the cell cycle. Thus, the expression of these agonist-specific marker genes is a potential determinant of agonist activity at the cellular level in the breast. Collectively, studies in the breast and uterine myometrium have identified several mechanisms whereby ER ligands modulate ER-mediated signaling and provide insights into the biology of tissue-specific agonist activity in hormone-responsive tissues. ^

An N-ethyl-n-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess

Cushing's syndrome, which is characterized by excessive circulating glucocorticoid concentrations, maybe due to ACTH-dependent or -independent causes that include anterior pituitary and adrenal cortical tumors, respectively. ACTH secretion is stimulated by CRH, and we report a mouse model for Cushing's syndrome due to an N-ethyl-N-nitrosourea (ENU) induced Crh mutation at -120 bp of the promoter region, which significantly increased luciferase reporter activity and was thus a gain-of-function mutation. Crh -120/+ mice, when compared with wild-type littermates, had obesity, muscle wasting, thin skin, hair loss, and elevated plasma and urinary concentrations of corticosterone. In addition, Crh-120/+ mice had hyperglycemia, hyperfructosaminemia, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, and hyperleptinemia but normal adiponectin. Crh -120/+ mice also had low bone mineral density, hypercalcemia, hypercalciuria, and decreased concentrations of plasma PTH and osteocalcin. Bone histomorphometry revealed Crh-120/+ mice to have significant reductions in mineralizing surface area, mineral apposition, bone formation rates, osteoblast number, and the percentage of corticoendosteal bone covered by osteoblasts, which was accompanied by an increase in adipocytes in the bone marrow. Thus, a mouse model for Cushing's syndrome has been established, and this will help in further elucidating the pathophysiological effects of glucocorticoid excess and in evaluating treatments for corticosteroid-induced osteoporosis.

Effect of Neutralization of Endogenous Follicle Stimulating Hormone (FSH) or Luteinizing Hormone (LH) on Ovarian Lipids in the Hamster: A Histochemical and Biochemical Evaluation

The effect of neutralizing FSH or LH on ovarian lipids in the cycling hamster was studied. In the normal cycling hamster on the day of proestrus, histochemical examination revealed the presence of sudanophilic lipids in the granulosa cells of the follicles and in the interstitium. A clear reduction in the intensity of lipid staining was observed on proestrus in the ovary of hamsters treated with FSH antiserum on the previous proestrus. Similar treatment with antiserum to LH, on the other hand, caused an accumulation of lipids in these structures. Estimation of the free and esterified fractions of cholesterol and triglycerides in the nonluteal tissue of the ovary of hamsters on proestrus following treatment with FSH antiserum on the previous proestrus revealed a significant reduction in all 3 lipid components. Even a short term deprivation of FSH caused a similar reduction in these lipids in the ovary. In contrast, treatment with LH antiserum either on the previous proestrus or on the previous day (diestrus-2) resulted in an enhancement in esterified cholesterol and triglycerides, while it caused a reduction in the free cholesterol fraction of the ovary on proestrus.It is suggested that though treatment with antisera to either FSH or LH causes a disruption in follicular maturation, their effect on lipid metabolism is different. A positive role for FSH and LH in maintaining normal sterol and triglyceride levels in the nonluteal ovarian tissue of cycling hamster is indicated.

Regioselective Deiodination of Iodothyronamines, Endogenous Thyroid Hormone Derivatives, by Deiodinase Mimics

Iodothyronine deiodinases (IDs) are mammalian selenoenzymes that play an important role in the activation and inactivation pound of thyroid hormones. It is known that iodothyronamines (TnAMs), produced by the decarboxylation of thyroid hormones, act as substrates for deiodinases. To understand whether decarboxylation alters the rate and/or regioselectivity of deiodination by using synthetic deiodinase mimics, we studied the deiodination of different iodothyronamines. The triiodo derivative 3,3',5-triiodothyronamine (T3AM) is deiodinated at the inner ring by naphthyl-based deiodinase mimics, which is similar to the deiodination of 3,3',5-triiodothyronine (T3). However, T3AM under-goes much slower deiodination than T3. Detailed experimental and theoretical investigations suggest that T3AM forms a weaker halogen bond with selenium donors than T3. Kinetic studies and single-crystal X-ray structures of T3 and T3AM reveal that intermolecular I center dot center dot center dot I interactions may play an important role in deiodination. The formation of hydrogen- and halogen-bonding assemblies, which leads to the formation of a dimeric species of T3 in solution, facilitates the interactions between the selenium and iodine atoms. In contrast, T3AM, which does not have I center dot center dot I interactions, undergoes much slower deiodination.

The Essential Role of Endogenous Ghrelin in Growth Hormone Expression during Zebrafish Adenohypophysis Development

Ghrelin, a multifunctional hormone, including potent GH stimulation activity, has been suggested to be important during embryonic development. Expression of ghrelin has been confirmed in the zebrafish pancreas during embryonic stages. Interfering with ghrelin function using two specific antisense morpholino oligonucleotides causes defects during zebrafish embryonic development. In ghrelin morphants the expression of GH was abolished in zebrafish somatotropes, whereas the expression patterns of the other key molecules involved in hypothalamic-pituitary development and distinct pituitary hormones genes remain largely intact at the appropriate time during zebrafish adenohypophysis development. Effective rescue of the ghrelin morphants with exogenous ghrelin mRNA showed that the correct gene had been targeted. Moreover, by analyzing the efficiencies of the ghrelin morphants rescue experiments with various forms of exogenous mutant ghrelin mRNAs, we also demonstrated the essentiality of the form acyl-ghrelin on GH stimulation during zebrafish adenohypophysis development. Our in vivo experiments, for the first time, also provided evidence of the existence of functional obestatin in the C-terminal part of zebrafish proghrelin peptides. Our research here has demonstrated that zebrafish is a unique model for functional studies of endogenous ghrelin, especially during embryonic development. (Endocrinology 150: 2767-2774, 2009)

Reasons for the variability in growth hormone (GH) responses to GHRH challenge:the endogenous hypothalamic-somatotroph rhythm (HSR)

The aims of this study were: (1) to test the possibility that pre-GHRH plasma GH values could reflect the functional status of the hypothalamic-somatotroph rhythm (HSR) at testing, and thus explain if it is responsible for the marked variability in GH responsiveness to GHRH challenge and (2) to see if exogenous somatostatin (SS) could disrupt this endogenous HSR and thus make the GH responses homogeneous. (1) Two to 14 GHRH acute tests (GRF-29, 1 µg/kg, i.v. bolus) were performed in 12 normal men and 10 normal women at the same time (0830 h) at random intervals (2 to 60 days). Blood samples to measure plasma GH were drawn at 15 min intervals before and after GHRH challenge. Given that the increments in pre-GHRH plasma GH values (I = value at 0 min minus value at -15 min) were highly correlated with either GHRH-elicited peaks of GH (men, r = 0.81; women, r = 0.69; P